Analyst consensus rating
Lakefront Biotherapeutics Analyst Rating: Hold
LKFT is rated Hold by 3 analysts with a $23.84 target. As of 2026-08-28.
Direct answer
Lakefront Biotherapeutics's consensus rating is Hold.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $23.84.
Forecast evidence checked August 28, 2026.
Get free Lakefront Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $29.44
- Average price target
- $23.84
- High price target
- $26.23
- Low price target
- $19.05
- Low target gap
- -35.3%
- Target upside
- -19%
- High target gap
- -10.9%
- Target range width
- 24.4%
- Consensus rating
- Hold
- Analysts
- 3
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lakefront Biotherapeutics?
Lakefront Biotherapeutics has a verified Hold consensus. The same dataset has an average price target of $23.84.
How far are Lakefront Biotherapeutics's low and high targets from the recorded price?
The low target implies -35.3%, while the high target implies -10.9%.
How many analysts are included in Lakefront Biotherapeutics's consensus?
The verified consensus includes 3 analysts.
How is Lakefront Biotherapeutics's target upside or downside calculated?
The average target of $23.84 is divided by the recorded price of $29.44, then one is subtracted to produce -19%. This does not guarantee a future return.
When was Lakefront Biotherapeutics's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.